The IP6K Inhibitor LI-2242 Ameliorates Diet-Induced Obesity, Hyperglycemia, and Hepatic Steatosis in Mice by Improving Cell Metabolism and Insulin Signaling
Biomolecules · 2023
DOI: 10.3390/biom13050868 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomolecules, 2023. Verfasst von Sandip Mukherjee und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Physiology, Saint Louis University School of Medicine, Saint Louis, MO 63104, USA. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease, Insulin Resistance, Hyperglycemia. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, NIMH NIH HHS, Saint Louis University (SLU).
Abstract (Originalsprache)
Obesity and nonalcoholic fatty liver disease (NAFLD) are global health concerns, and thus, drugs for the long-term treatment of these diseases are urgently needed. We previously discovered that the inositol pyrophosphate biosynthetic enzyme IP6K1 is a target in diet-induced obesity (DIO), insulin resistance, and NAFLD. Moreover, high-throughput screening (HTS) assays and structure−activity relationship (SAR) studies identified LI-2242 as a potent IP6K inhibitor compound. Here, we tested the efficacy of LI-2242 in DIO WT C57/BL6J mice. LI-2242 (20 mg/kg/BW daily, i.p.) reduced body weight in DIO mice by specifically reducing the accumulation of body fat. It also improved glycemic parameters and reduced hyperinsulinemia. LI-2242-treated mice displayed reduced the weight of various adipose tissue depots and an increased expression of metabolism- and mitochondrial-energy-oxidation-inducing genes in these tissues. LI-2242 also ameliorated hepatic steatosis by reducing the expression of genes that enhance lipid uptake, lipid stabilization, and lipogenesis. Furthermore, LI-2242 enhances the mitochondrial oxygen consumption rate (OCR) and insulin signaling in adipocytes and hepatocytes in vitro. In conclusion, the pharmacologic inhibition of the inositol pyrophosphate pathway by LI-2242 has therapeutic potential in obesity and NAFLD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology and Physiology, Saint Louis University School of Medicine, Saint Louis, MO 63104, USA.
- Lieber Institute for Brain Development and Department of Pharmacology, Johns Hopkins University School of Medicine, 855 North Wolfe Street Suite 300, Baltimore, MD 21205, USA.
ORCID-Profile: James C Barrow
Förderung
- NIDDK NIH HHS
- NIMH NIH HHS
- Saint Louis University (SLU)
Zitieren
APA
Mukherjee, S., Chakraborty, M., Haubner, J., Ernst, G., DePasquale, M., Carpenter, D., Barrow, J. C., & Chakraborty, A. (2023). The IP6K Inhibitor LI-2242 Ameliorates Diet-Induced Obesity, Hyperglycemia, and Hepatic Steatosis in Mice by Improving Cell Metabolism and Insulin Signaling. Biomolecules. https://doi.org/10.3390/biom13050868
Vancouver
Mukherjee S, Chakraborty M, Haubner J, Ernst G, DePasquale M, Carpenter D, et al. The IP6K Inhibitor LI-2242 Ameliorates Diet-Induced Obesity, Hyperglycemia, and Hepatic Steatosis in Mice by Improving Cell Metabolism and Insulin Signaling. Biomolecules. 2023. doi:10.3390/biom13050868
BibTeX
@article{Mukherjee2023,
author = {Mukherjee, Sandip and Chakraborty, Molee and Haubner, Jake and Ernst, Glen and DePasquale, Michael and Carpenter, Danielle and Barrow, James C and Chakraborty, Anutosh},
title = {The IP6K Inhibitor LI-2242 Ameliorates Diet-Induced Obesity, Hyperglycemia, and Hepatic Steatosis in Mice by Improving Cell Metabolism and Insulin Signaling},
journal = {Biomolecules},
year = {2023},
doi = {10.3390/biom13050868}
}
EUVIMED